open access

Vol 77, No 2 (2009)
REVIEWS
Published online: 2009-03-16
Submitted: 2013-02-22
Get Citation

Dilemmas in the curative treatment of lung cancer in the elderly patients

Lucyna Kępka
Pneumonol Alergol Pol 2009;77(2):166-172.

open access

Vol 77, No 2 (2009)
REVIEWS
Published online: 2009-03-16
Submitted: 2013-02-22

Abstract

Patients aged 70 years and older accounted for 42% of all lung cancer deaths in Poland in 2005. Although the incidence of lung cancer in elderly people is growing in Poland, like in other developed countries, the standards of treatment for this subset of population are not well established. Prospective elderly-specific trials concerning curative treatment are lacking. The results from prospective trials including elderly participants show similar effectiveness as in younger population at the expense of higher toxicity. Selection bias may limit the ability to generalize results of clinical trials to the entire population of elderly people. Methods of curative treatment (surgery, radiotherapy, chemotherapy as adjuvant for non-small cell lung cancer and basic treatment for limited-stage small cell lung cancer) are discussed. Some treatment options and modifications of standard strategies which are particularly promising in elderly patients, as VADS surgery, stereotactic radiotherapy or abbreviated treatment for SCLC, are presented.

Abstract

Patients aged 70 years and older accounted for 42% of all lung cancer deaths in Poland in 2005. Although the incidence of lung cancer in elderly people is growing in Poland, like in other developed countries, the standards of treatment for this subset of population are not well established. Prospective elderly-specific trials concerning curative treatment are lacking. The results from prospective trials including elderly participants show similar effectiveness as in younger population at the expense of higher toxicity. Selection bias may limit the ability to generalize results of clinical trials to the entire population of elderly people. Methods of curative treatment (surgery, radiotherapy, chemotherapy as adjuvant for non-small cell lung cancer and basic treatment for limited-stage small cell lung cancer) are discussed. Some treatment options and modifications of standard strategies which are particularly promising in elderly patients, as VADS surgery, stereotactic radiotherapy or abbreviated treatment for SCLC, are presented.
Get Citation

Keywords

lung cancer; elderly; radiotherapy; chemotherapy

About this article
Title

Dilemmas in the curative treatment of lung cancer in the elderly patients

Journal

Advances in Respiratory Medicine

Issue

Vol 77, No 2 (2009)

Pages

166-172

Published online

2009-03-16

Bibliographic record

Pneumonol Alergol Pol 2009;77(2):166-172.

Keywords

lung cancer
elderly
radiotherapy
chemotherapy

Authors

Lucyna Kępka

References (45)
  1. Szczuka I, Roszkowski-Śliż K. Rak płuca w sce w latach 1970–2004. Pneumonol Alergol Pol. 2008; 76: 19–28.
  2. Owonikoko TK, Ragin CC, Belani CP, et al. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol. 2007; 25(35): 5570–5577.
  3. Jassem J, Drosik K, Dziadziuszko R, et al. Systemowe leczenie raka płuca i międzybłoniaka opłucnej: uaktualnione zalecenia oparte na wynikach wiarygodnych badań klinicznych. Pneumonol Alergol Pol. 2008; 76: 44–52.
  4. Asmis TR, Ding K, Seymour L, et al. National Cancer Institute of Canada Clinical Trials Group. Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. J Clin Oncol. 2008; 26(1): 54–59.
  5. Jatoi A, Hillman S, Stella P, et al. North Central Cancer Treatment Group. Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group. J Clin Oncol. 2005; 23(36): 9113–9119.
  6. Balducci L. Geriatric oncology: challenges for the new century. Eur J Cancer. 2000; 36(14): 1741–1754.
  7. Brock MV, Kim MP, Hooker CM, et al. Pulmonary resection in octogenarians with stage I nonsmall cell lung cancer: a 22-year experience. Ann Thorac Surg. 2004; 77(1): 271–277.
  8. Port JL, Kent M, Korst RJ, et al. Surgical resection for lung cancer in the octogenarian. Chest. 2004; 126(3): 733–738.
  9. Rostad H, Strand TE, Naalsund A, et al. Lung cancer surgery: the first 60 days. A population-based study. Eur J Cardiothorac Surg. 2006; 29(5): 824–828.
  10. Finlayson E, Fan Z, Birkmeyer JD. Outcomes in octogenarians undergoing high-risk cancer operation: a national study. J Am Coll Surg. 2007; 205(6): 729–734.
  11. Tanoue LT, Gettinger S. Treatment of lung cancer in older patients. Clin Chest Med. 2007; 28(4): 735–49, vi.
  12. Shaw JP, Dembitzer FR, Wisnivesky JP, et al. Video-assisted thoracoscopic lobectomy: state of the art and future directions. Ann Thorac Surg. 2008; 85(2): S705–S709.
  13. Pennathur A, Abbas G, Christie N, et al. Video assisted thoracoscopic surgery and lobectomy, sublobar resection, radiofrequency ablation, and stereotactic radiosurgery: advances and controversies in the management of early stage non-small cell lung cancer. Curr Opin Pulm Med. 2007; 13(4): 267–270.
  14. Jeremic B, Classen J, Bamberg M. Radiotherapy alone in technically operable, medically inoperable, early-stage (I/II) non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2002; 54(1): 119–130.
  15. Nagata Y, Takayama K, Matsuo Y, et al. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys. 2005; 63(5): 1427–1431.
  16. Zimmermann FB, Geinitz H, Schill S, et al. Stereotactic hypofractionated radiation therapy for stage I non-small cell lung cancer. Lung Cancer. 2005; 48(1): 107–114.
  17. Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006; 24(30): 4833–4839.
  18. Vrdoljak E, Mise K, Sapunar D, et al. Survival analysis of untreated patients with non-small-cell lung cancer. Chest. 1994; 106(6): 1797–1800.
  19. McGarry RC, Song G, des Rosiers P, et al. Observation-only management of early stage, medically inoperable lung cancer: poor outcome. Chest. 2002; 121(4): 1155–1158.
  20. Raz DJ, Zell JA, Ou SHI, et al. Natural history of stage I non-small cell lung cancer: implications for early detection. Chest. 2007; 132(1): 193–199.
  21. van Meerbeeck JP, Kramer GW, Van Schil PEY, et al. European Organisation for Research and Treatment of Cancer-Lung Cancer Group. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst. 2007; 99(6): 442–450.
  22. Albain KS, Swann RS, Rusch VR, et al. Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs. CT/RT followed by surgical resection for stage IIIA (pN2) non-small cell lung cancer (NSCLC): outcomes update of North erican Intergroup 0139 (RTOG 9309). Proc Am Soc Clin Oncol. 2005; 23: 624.
  23. Pignon T, Gregor A, Schaake Koning C, et al. Age has no impact on acute and late toxicity of curative thoracic radiotherapy. Radiother Oncol. 1998; 46(3): 239–248.
  24. Baumann M. Is curative radiation therapy in elderly patients limited by increased normal tissue toxicity? Radiother Oncol. 1998; 46(3): 225–227.
  25. Werner-Wasik M, Scott C, Cox J, et al. Recursive partitioning analysis of 1999 radiation therapy oncology group (RTOG) patients with locally-advanced non–small-cell lung cancer (LA-NSCLC): Identification of five groups with different survival. International Journal of Radiation Oncology*Biology*Physics. 2000; 48(5): 1475–1482.
  26. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ. 1995; 311(7010): 899–909.
  27. Jassem J. The role of radiotherapy in lung cancer: where is the evidence? Radiother Oncol. 2007; 83(2): 203–213.
  28. Rowell NP. O’Rourke N.P. Concurrent chemoradiotherapy in non-small cell lung cancer. . The Cochrane Database of Systematic Reviews. 2004.
  29. Movsas B, Scott C, Sause W, et al. The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies. International Journal of Radiation Oncology*Biology*Physics. 1999; 45(5): 1143–1149.
  30. Schild SE, Stella PJ, Geyer SM, et al. North Central Cancer Treatment Group. The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol. 2003; 21(17): 3201–3206.
  31. Sequist LV, Lynch TJ. Aggressive treatment for the fit elderly with non-small-cell lung cancer? Yes! J Clin Oncol. 2003; 21(17): 3186–3188.
  32. Extermann M, Albrand G, Chen H, et al. Are older French patients as willing as older American patients to undertake chemotherapy? J Clin Oncol. 2003; 21(17): 3214–3219.
  33. Baumann M, Herrmann T, Koch R, et al. Continuous hyperfractionated accelerated radiotherapy — weekend less (CHARTWEL) versus conventionally fractionated (CF) in non-small-cell lung cancer (NSCLC): First results of a phase III randomised multicentre trial (ARO 97-1). Eur J Cancer. 2005; 3: 323.
  34. Kępka L. Zbadanie częstości i przyczyn niepowodzeń w klatce piersiowej po trójwymiarowej konformalnej radioterapii u chorych na niedrobnokomórkowego raka płuca. (Rozprawa habilitacyjna). Centrum Onkologii – Instytut im. M. Skłodowskiej-Curie. Warszawa, 2006.
  35. Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 1992; 327(23): 1618–1624.
  36. Aupérin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med. 1999; 341(7): 476–484.
  37. Quon H, Shepherd FA, Payne DG, et al. The influence of age on the delivery, tolerance, and efficacy of thoracic irradiation in the combined modality treatment of limited stage small cell lung cancer. Int J Radiat Oncol Biol Phys. 1999; 43(1): 39–45.
  38. Yuen AR, Zou G, Turrisi AT, et al. Similar outcome of elderly patients in intergroup trial 0096: Cisplatin, etoposide, and thoracic radiotherapy administered once or twice daily in limited stage small cell lung carcinoma. Cancer. 2000; 89(9): 1953–1960.
  39. Schild SE, Stella PJ, Brooks BJ, et al. Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderly. Cancer. 2005; 103(11): 2349–2354.
  40. Jeremic B, Shibamoto Y, Acimovic L, et al. Carboplatin, etoposide, and accelerated hyperfractionated radiotherapy for elderly patients with limited small cell lung carcinoma: a phase II study. Cancer. 1998; 82(5): 836–841.
  41. Murray N, Grafton C, Shah A, et al. Abbreviated treatment for elderly, infirm, or noncompliant patients with limited-stage small-cell lung cancer. J Clin Oncol. 1998; 16(10): 3323–3328.
  42. De Ruysscher D, Pijls-Johannesma M, Bentzen SM, et al. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol. 2006; 24(7): 1057–1063.
  43. Videtic G. M.M., Belderbos .S.A., Kong F.-M., Kepka L., Martel M., eremić B. Perspectives on elective nodal irradiation in lung cancer: Report from the 2006 IAEA consultants’ meeting. Part II: Small-Cell Lung Cancer (SCLC). Int J Radiat Oncol Biol Phys. 2008; 72: 327–334.
  44. Lee JJ, Bekele BN, Zhou X, et al. Decision analysis for prophylactic cranial irradiation for patients with small-cell lung cancer. J Clin Oncol. 2006; 24(22): 3597–3603.
  45. NCCN Clinical Practice Guidelines in Oncology. Small Cell Lung Cancer. www.nccn.org..

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl